Overview

• Participants in the 40-week placebo-controlled trial saw blood sugar levels drop by 1.3% to 1.6% across doses, mirroring results from weekly injectable GLP-1 therapies.
• At the highest 36 mg dose, patients lost an average of 7.9% of body weight—about 16 pounds—comparable to leading injectable treatments.
• Diarrhea, nausea, indigestion and constipation were the most common adverse events, prompting discontinuation in up to 8% of participants versus 1% on placebo.
• Lilly plans to release obesity-only trial results in the third quarter and submit weight-management data to regulators by year-end, with diabetes approval targeted in 2026.
• Orforglipron’s daily oral format eliminates cold-chain storage and strict dosing requirements, potentially reducing costs and expanding global access compared with injectables.